venetoclax: an unmet need in r/r mantle cell lymphoma after btk inhibitors
Published 5 years ago • 211 plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
2:06
the role of venetoclax in r/r mcl & options for patients who progress on venetoclax
-
5:50
venetoclax and r2 in mantle cell lymphoma
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
1:30
final results of the aim study of ibrutinib and venetoclax in mantle cell lymphoma
-
3:06
durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
-
6:24
indiko biochemistry analyzer demonstration
-
2:25
venetoclax for aml
-
10:42
understanding mantle cell lymphoma with jia ruan, md, ph.d.
-
2:07
novel treatments for mantle cell lymphoma
-
2:00
preliminary results of the aim trial of ibrutinib and venetoclax in mantle cell lymphoma
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
1:44
treating mantle cell lymphoma: past approaches and future perspectives
-
1:03
advancements in mcl treatment
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
5:45
treatment effectiveness of venetoclax-based therapy after btki exposure in cll/sll
-
11:35
molecules in vr: venetoclax, the first approved bcl-2 antagonist for chronic lymphocytic leukemia
-
2:06
odronextamab in car-t relapsed diffuse large b-cell lymphoma
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
0:45
difference between quality of life & patient-reported outcomes
-
3:03
outcomes following venetoclax monotherapy in patients with r/r wm in the real-world setting
-
2:37
the changing role of autosct in mantle cell lymphoma: the impact of novel agents
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria